Search This Blog

Thursday, June 1, 2023

Ionis: late-stage clinical progress in hereditary angioedema

 

  • Two-year treatment with donidalorsen in the Phase 2 open label study resulted in consistent, sustained protection from HAE attacks
  • Completed enrollment in the Phase 3 OASIS-HAE study
  • Topline Phase 3 results expected in H1 2024
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)